Zhaoke Ophthalmology's (HKG:6622) new drug application for core product Cyclosporine (CsA) Ophthalmic Gel has been accepted by China's National Medical Products Administration, a Monday Hong Kong bourse filing said.
The product is being developed by the ophthalmic pharmaceutical company in China for the treatment of moderate to severe dry eye disease.